Fioricet is Non-Controlled Substance In Missouri. The following questions and explanations are changed and affected.

Section 4 Question 3 and Section 2 Explanation 4.

Section 1 Q.18 Entire Question is updated: 

Which of the following is/are TRUE about labeling the dispensing container for Lipitor 10 mg or its generic equivalent?

I. Lipitor 10 mg

II. Atorvastatin (Sandoz) 10 mg - Substituted for Lipitor

III. Atorvastatin (Mylan) 10 mg - Substituted for Lipitor

a. I only
b. I and II only
c. II and III only
d. All

Answer: All, [Texas Administrative Code Title 22, Part 15, Chapter 291, Subchpater B, 291.33(c)(7)(A)(vii)(viii)].

No drug product may be dispensed unless the prescription label discloses the brand name and strength, or the generic name, strength, and manufacturer or distributor of the drug product dispensed unless the prescribing practitioner requests omission of the above information.

If the pharmacist has selected a generically equivalent drug pursuant to the provisions of the Act, Chapter 562, the statement "Substituted for Brand Prescribed" or "Substituted for 'Brand Name'" where "Brand Name" is the actual name of the brand name product prescribed;

The name shall be either:

(-a-). the brand name; or

(-b-). if no brand name, then the generic name and name of the manufacturer or distributor of such generic drug.

The name of the manufacturer or distributor may be reduced to an abbreviation or initials, provided the abbreviation or initials are sufficient to identify the manufacturer or distributor.

For combination drug products or non-sterile compounded drug products having no brand name, the principal active ingredients shall be indicated on the label.

Section 2 Q.15 Explanation is changed: 

The administrator must return an unused official prescription form to the director department not later than the 30th day after the date the individual completes or terminates all training programs.

Section 3 Q.9 Entire Question is updated: 

The transfer of original prescription drug order information for Tylenol No.3 shall be communicated directly between:

I. two pharmacists
II. a pharmacist and a pharmacy-intern
III. two pharmacy-interns

a. I only
b. I and II only
c. II and III only
d. All

Answer: I and II only, [Texas Administrative Code Title 22, Part 15, Chapter 291, Subchapter B, 291.34(g)(3)].

Transfer of prescription drug order information. For the purpose of refill or initial dispensing, the transfer of original prescription drug order information is permissible between pharmacies, subject to the following requirements:

(A). the transfer of original prescription drug order information for controlled substances listed in Schedule III, IV, or V is permissible between pharmacies on a one-time basis;

(B). the transfer of original prescription drug order information for dangerous drugs is permissible between pharmacies without limitation up to the number of originally authorized refills;

(C). The transfer is communicated orally by telephone or via facsimile directly by a pharmacist to another pharmacist; by a pharmacist to a student-intern, extended-intern, or resident-intern; or by a student-intern, extended-intern, or resident-intern to another pharmacist.....

Section 5 Q.26 Entire Question is updated: 

Which of the following is/are considered to be (an) approved program(s) for continuing education requirements?

I. ACPE
II. CME-1
III. ARSD

a. I only
b. I and II only
c. II and III only
d. All

Answer: I and II only, [Texas Administrative Code Title 22, Part 15, Chapter 295, 295.8(e)(1) and (e)(13)].

Programs approved by the Accreditation Council for Pharmacy Education (ACPE), the American Medical Association (AMA) as Category 1 Continuing Medical Education (CME) and accredited by the Accreditation Council for Continuing Medical Education subject to the following conditions.

(A). Pharmacists may receive credit for the completion of the same CME course only once during a license period.

(B). Pharmacists who present approved CME programs may receive credit for the time expended during the actual presentation of the program. Pharmacists may receive credit for the same presentation only once during a license period.

(C). Proof of completion of a CME course shall contain the following information:

(i). name of the participant;

(ii). title and completion date of the program;

(iii). name of the approved provider sponsoring or cosponsoring the program;

(iv). number of contact hours and/or CEUs awarded; and

(v). a dated certifying signature of the approved provider.

Section 5 Q.14 Explanation and Answer are changed: 

Twice each month, Daily, [3 Colorado Code of Regulation (CCR) 719-1-23.00.30].

Every prescription drug outlet must ensure that all controlled substance dispensing transactions are reported to the PDMP on a daily basis by no later than the outlet’s next regular business day.

Every prescription drug outlet must ensure controlled substance dispensing transactions are reported to the PDMP twice each month on the following schedule:
 
a. For dispensing transactions from the first through the 15th day of each month, data shall be transmitted to the PDMP between the 16th and 25th day of that month.
 
b. For dispensing transactions from the 16th through the last day of the month, data shall be transmitted to the PDMP between the 1st through the 10th day of the subsequent month.
 
c. If the prescription drug outlet does not dispense any controlled substances for the reporting period, it must enter a “zero” entry or will be considered non-compliant.

Section 4 Q.18 Explanation 18 is changed: 

Those subdivisions list the “combination” Schedule III controlled substances -i.e. Vicodin and the like.

Section 1 Q.29 Explanation 29: Alfentanil is a schedule I controlled substamce under the Maryland State Pharmacy Law. It is a schedule II, however, under the Federal Pharmacy Law.

Alfentanil (Alfenta) **Exception**(Schedule I controlled substance under Maryland Law)

Section 5 Q.7: Drug Name In The Question Is Changed From Vicodin To Tylenol No.3....

Mr. Pellete is visiting Texas from Maryland. On his stay in Texas, he suffers from severe tooth pain. Upon request, his physician in Maryland calls a pharmacist in Texas and asks him to dispense a 3-day supply of Vicodin Tylenol No. 3.

Section 3 Q.5: Explanation Is Changed....

A pharmacist may engage in the administration of Zoster and Influenza.

a. An immunizing pharmacist may administer vaccinations or immunizations only if the vaccinations or immunizations are recommended or required by the Centers for Disease Control and Prevention and administered to persons at least 18 years of age pursuant to a specific prescription order.

b. An immunizing pharmacist may administer the vaccinations or immunizations listed in subdivisions (1) through (5) of this subsection to persons at least 18 years of age if the vaccinations or immunizations are administered under written protocols.

(1). Pneumococcal polysaccharide or pneumococcal conjugate vaccines.

(2). Herpes zoster vaccine.

(3). Hepatitis B vaccine.

(4). Meningococcal polysaccharide or meningococcal conjugate vaccines.

(5). Tetanus-diphtheria, tetanus and diphtheria toxoids and pertussis, tetanus and diphtheria toxoids and acellular pertussis, or tetanus toxoid vaccines. However, a pharmacist shall not administer any of these vaccines if the patient discloses that the patient has an open wound, puncture, or tissue tear.

(c). An immunizing pharmacist may administer the influenza vaccine to persons at least 14 years of age.

(d). An immunizing pharmacist who administers a vaccine or immunization to any patient pursuant to this section shall do all of the following:

(1). Maintain a record of any vaccine or immunization administered to the patient in a patient profile.

(2). Within 72 hours after administration of the vaccine or immunization, notify any primary care provider identified by the patient. If the patient does not identify a primary care provider, the immunizing pharmacist shall direct the patient to information describing the benefits to a patient of having a primary care physician, prepared by any of the following:

1. North Carolina Medical Board,

2. North Carolina Academy of Family Physicians,

3. North Carolina Medical Society, or Community Care of North Carolina.

(3). Except for influenza vaccines, access the North Carolina Immunization Registry prior to administering the vaccine or immunization and record any vaccine or immunization administered to the patient in the registry within 72 hours after the administration.

In the event the registry is not operable, an immunizing pharmacist shall report as soon as reasonably possible.

Section 3 Q.9: Answer choices are corrected....

a. I only
b. I and II only
c. II and III only
d. All

a. True
b. False

Section 5 Q.7: Entire Question Is Updated....

Q. 127 Which of the following statement are TRUE about pharmacists administering vaccines, according to North Carolina State Pharmacy Law?

I. The pharmacist shall not administer vaccines to patients less than 18 years of age.

II. The pharmacist or pharmacy intern may administer immunization.

III. The Physician and the Immunizing Pharmacist shall review the Written Protocol at least biennially and revise it if necessary.

a. I only
b. I and II only
c. II and III only
d. All

Answer: I and II are true, [21 NCAC 46 .2507 and North Carolina 90-85.15B].

The pharmacist or pharmacy intern who is under the direct, in-person supervision of an Immunizing Pharmacist may administer immunization.

"Written Protocol" is a document prepared, signed, and dated by the Physician and Immunizing Pharmacist that shall contain the following:

(A). the name of the Physician responsible for authorizing the Written Protocol;

(B). the name of the Immunizing Pharmacist authorized to administer vaccines;

(C). the immunizations or vaccinations that may be administered by the Immunizing Pharmacist;

(D). the screening questionnaires and safety procedures that shall at least include the then-current minimum standard screening questionnaire and safety procedures adopted by the Medical Board, the Board of Nursing, and the Board of Pharmacy pursuant to S.L. 2013-246, s. 6, and available at the Board of Pharmacy's office and on its website (www.ncbop.org).

(E). the procedures to follow, including any drugs required by the Immunizing Pharmacist for treatment of the patient, in the event of an emergency or adverse event following vaccine administration;

(F). the reporting requirements by the Immunizing Pharmacist to the Physician, including content and time frame; and

(G). the locations at which the Immunizing Pharmacist may administer immunizations or vaccinations.

The Physician and the Immunizing Pharmacist shall review the Written Protocol at least annually (NOT biennially) and revise it if necessary.

An Immunizing Pharmacist who, because of physical disability, is unable to obtain a current provider level CPR certification pursuant to G.S. 90-85.3(i1)(1), may administer vaccines in the presence of a pharmacy technician or pharmacist who holds a current provider level CPR certification.

With each dose of vaccine, either the Immunizing Pharmacist or a Pharmacy Intern shall give the most current vaccine information regarding the purpose, risks, benefits, and contraindications of the vaccine to the patient or legal representative.

The Immunizing Pharmacist or Pharmacy Intern must ensure that the patient or legal representative has the opportunity to read, or to have read to him or her, the information provided and to have any questions answered prior to administration of the vaccine.

Section 1 Q.8 and Section 2 Q.25: Date Formate Requirement On Prescription Is Changed....

...and a notation of the date, with the abbreviated month written out on the face of the prescription.

and a notation of the date in numerical, month/day/year format, or with the abbreviated month written out, or the month written out in whole.

Section 1 Q.12: Continuing Education Records Retention Requirement Is Changed....

Each pharmacist shall retain documentation of participation in continuing education programs required for license renewal for not less than FOUR years after.... not less than TWO years after....

Section 1 Q.20: Answer Explanation 20 is Changed....

This method of destruction does not require prior approval from D.E.A., but does require that a copy of the completed and witnessed D.E.A. Form 41 be mailed to D.E.A. within one (1) business day after destruction.

Section 1 Q.22 and Section 3 q.7: Terms Are Changed...

Receiving Pharmacy is now Originating Pharmacy and

Supplying Pharmacy is now Central Fill Pharmacy

Section 3 Q.9: Vicodin shall be replaced with Tylenol No. 3.

Section 3 Q.11, Q.13 and Section 5 Q.29: All questions are replaced with new questions.

Section 3 Q.25: Patient Profile Records Retention Requirement Is Changed....

Such profiles shall be maintained at the pharmacy wherein the ordering and dispensing originated for a period of 2 years 4 years.

Section 5 Q.7: "Transfer of legend drugs and controlled substances" Records Retention Requirement Is Changed....

Both the new permit and the old permit must keep appropriate records for two (2) years 4 years for the transfer of legend drugs and controlled substances.

Pharmacists in California may now provide naloxone, themedication that can help to reverse the effects of an opioid overdose, without a prescription after the California State Board of Pharmacy approved new emergency regulations (PDF). To be eligible to dispense the drug under the new regulations, pharmacists must complete one hour of continuing education (CE) on the use of the drug, notes a press release (PDF) from the Board. When dispensing the drug, pharmacists must screen for any hypersensitivity, and must provide the recipient with training in opioid overdose prevention, recognition, response, and on the administration of the drug.

The pharmacist must also provide the recipient a naloxone fact sheet (PDF), which has been approved by the Board. In October 2014, NABP released a statement supporting an active role for pharmacists in increasing access to naloxone. NABP is also active in educating consumers about prescription drug abuse and prevention through the AWARXE® Prescription Drug Safety Program, and information and educational resources on these topics are available on the program’s website.

1. Continuing Pharmacy Education Requirements Are Changed

(6). Continuing pharmacy education credit accumulated in excess of the required 30 contact hours for biennial license renewal cannot be carried forward.

(7). A maximum of 20 contact hours (2.0 CEU) may be earned in any licensing cycle by preparing and presenting CE programs.

Pharmacists presenting CE programs may earn one contact hour (0.1 CEU) for preparation time of one hour or more, plus credit for the actual contact hour time of the presentation.

A pharmacist must show content of the course, and a description of the intended audience (e.g., pharmacists, physicians, nurses). Public service programs, such as presentations to school children or service clubs, are not eligible for continuing education credit.

(8). Pharmacists taking post graduate studies applicable to graduate or professional degrees may submit the course syllabus and evidence of satisfactory completion of the course for continuing education credit approval by the Board.

(9). The Board may approve up to 26 contact hours of CE credit for pharmacists who have successfully completed nationally certified Disease State Management courses.

The following questions are affected in our quiz.

1. Section 1. Question 1

2. Section 1. Question 5

3. Section 1. Question 15

4. Section 1. Question 25

2. Section 2 Q.18 Reporting Requirement To The DEA Is Changed.

(2). When there are reasonable grounds to believe that drugs have been stolen, the pharmacist shall immediately 1 business day notify the Board.

3. Pharmacy Technician Certification Examination Options Are Changed.

(2). The Institute for the Certification of Pharmacy Technicians (ICPT) The National Health career Association (NHA).

The following questions are affected in our quiz.

1. Section 1. Question 24

2. Section 2. Question 22

4. Storing and Retrieving Records Requirements Are Changed. Section 3, Question 6

I is true, [OAR 855-041-1160(6)].

1. All records and documentation required by OAR 855 Division 041 must be retained for three years and made available to the Board for inspection upon request.

2. Records must be stored onsite for at least one year and

3. Records for second and third year may be stored in a secured off-site location if retrievable within three business days.

4. Records and documentation may be written, electronic or a combination of the two.

Unless specified otherwise, all records and documentation required by OAR 855 Division 041 must be retained for three years and made available to the Board for inspection upon request.

Records must be stored onsite for at least one year and may be stored in a secured off-site location if retrievable within three business days.

Records and documentation may be written, electronic or a combination of the two.